Cure8 news brief
An FDA approval for subcutaneous Skyrizi (risankizumab) induction dosing could change treatment options and access for adults with moderate to severe Crohn’s disease. Patients and clinicians will want to know how this fits with other biologics and what the approved dosing and safety profile are.
Adults with Crohn’s disease; patients on or considering biologic therapy; gastroenterologists/IBD clinicians; researchers and patient advocates tracking drug approvals.
AbbVie reported Q3 financial results and noted multiple regulatory and clinical updates across its pipeline. One of the items called out in the company summaries and press releases is FDA approval of Skyrizi for subcutaneous induction dosing in adults with moderate to severe Crohn’s disease; the company is also pursuing approval in the EU.
This article is a market/earnings recap (from TradingView) that aggregates AbbVie press-release items and earnings commentary rather than presenting clinical data or prescribing information. It does not provide detailed trial results, dosing schedules, safety information, or guidance about how this approval affects individual treatment decisions.
This is a business/earnings summary that cites AbbVie press releases. It does not contain full clinical details or the FDA label text; verify specifics from the FDA announcement or AbbVie.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
